Additionally, CEO Geoff Martha offered some insights into the Diabetes unit’s product pipeline during the Goldman Sachs global healthcare conference. Medtronic’s diabetes pipeline includes a next-generation continuous glucose monitor (CGM) sensor that is half the size of the company’s present sensor.
The medtech giant announced that it received FDA approval for MiniMed 780G with the Guardian 4 sensor in April. Medtronic’s new artificial pancreas system offers meal detection technology. It provides automatic adjustments and corrections to sugar levels every five minutes. This occurs for both basal (background) and bolus (mealtime) insulin needs.
Company officials called it a “monumental improvement” on existing diabetes offerings at Medtronic.
Get the full story at our sister site, Drug Delivery Business News.
